HK1044352A1 - Envelope gene-deficient virus vector of paramyxoviridae - Google Patents

Envelope gene-deficient virus vector of paramyxoviridae

Info

Publication number
HK1044352A1
HK1044352A1 HK02105976A HK02105976A HK1044352A1 HK 1044352 A1 HK1044352 A1 HK 1044352A1 HK 02105976 A HK02105976 A HK 02105976A HK 02105976 A HK02105976 A HK 02105976A HK 1044352 A1 HK1044352 A1 HK 1044352A1
Authority
HK
Hong Kong
Prior art keywords
gene
deficient
virus
successfully
paramyxoviridae
Prior art date
Application number
HK02105976A
Other languages
English (en)
Inventor
Kaio Kitazato
Tsugumine Shu
Hidekazu Kuma
Yasuji Ueda
Makoto Asakawa
Mamoru Hasegawa
Akihiro Iida
Fumino Tokitou
Takahiro Hirata
Tsuyoshi Tokusumi
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Publication of HK1044352A1 publication Critical patent/HK1044352A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18845—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C12N2760/18862—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK02105976A 1999-05-18 2002-08-15 Envelope gene-deficient virus vector of paramyxoviridae HK1044352A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20073999 1999-05-18
PCT/JP2000/003195 WO2000070070A1 (fr) 1999-05-18 2000-05-18 Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe

Publications (1)

Publication Number Publication Date
HK1044352A1 true HK1044352A1 (en) 2002-10-18

Family

ID=16429375

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105976A HK1044352A1 (en) 1999-05-18 2002-08-15 Envelope gene-deficient virus vector of paramyxoviridae

Country Status (12)

Country Link
EP (1) EP1186667B1 (de)
JP (2) JP3602058B2 (de)
KR (2) KR20070058607A (de)
CN (1) CN1330767C (de)
AT (1) ATE367445T1 (de)
AU (1) AU4614600A (de)
CA (1) CA2368948C (de)
DE (1) DE60035589T2 (de)
DK (1) DK1186667T3 (de)
ES (1) ES2288473T3 (de)
HK (1) HK1044352A1 (de)
WO (1) WO2000070070A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241617B2 (en) 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
WO2000001837A1 (fr) * 1998-07-03 2000-01-13 Dnavec Research Inc. Vecteur de virus a arn a brin negatif
US7226786B2 (en) 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
KR100774796B1 (ko) * 2000-01-19 2007-11-07 가부시키가이샤 디나벡크 겐큐쇼 파라믹소바이러스 벡터의 혈관으로의 유전자 도입용도
KR20070094989A (ko) 2000-03-30 2007-09-27 가부시키가이샤 디나벡크 겐큐쇼 센다이바이러스 벡터를 사용한 ａｉｄｓ 바이러스 백신
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
AU2002224113A1 (en) 2000-11-27 2002-06-03 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof
HUP0500244A3 (en) 2001-01-19 2011-03-28 Vironovative Bv A virus causing respiratory tract illness in suspectible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
FR2826010B1 (fr) * 2001-06-14 2005-02-25 Mahmood Salman Al Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales
CN1633599A (zh) * 2001-09-18 2005-06-29 株式会社载体研究所 检查和制造降低了粒子形成能力的(－)链rna载体的方法
CA2743750A1 (en) 2002-02-21 2003-09-04 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus
US7402427B2 (en) 2002-04-30 2008-07-22 Dnavec Research Inc. Vectors with modified protease-dependent tropism
KR100587388B1 (ko) * 2003-02-14 2006-06-08 주식회사 효성 고강도 폴리비닐알코올 섬유의 제조방법 및 그로부터수득되는 고강도 폴리비닐알코올 섬유
MXPA05011268A (es) * 2003-04-25 2006-06-20 Medimmune Vaccines Inc Sistemas de expresion de virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metaneumovirus.
US7585667B2 (en) * 2003-06-13 2009-09-08 The United States Of America As Represented By The Department Of Health And Human Services Negative strand RNA virus replicon
WO2005042737A1 (ja) 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
WO2005067981A1 (ja) 2004-01-13 2005-07-28 Dnavec Research Inc. 免疫刺激性サイトカインをコードするマイナス鎖rnaウイルスベクターを用いる腫瘍の遺伝子治療
EP1717317A4 (de) * 2004-01-22 2009-02-11 Dnavec Research Inc Verfahren zur herstellung viraler negativstrang-rna-vektoren unter verwendung eines den cytomegalovirus-enhancer und den beta-actin-promotor aus huhn umfassenden hybridpromotors
CN1934257A (zh) * 2004-01-22 2007-03-21 株式会社载体研究所 病毒载体的制备方法
WO2005097988A1 (ja) * 2004-03-23 2005-10-20 Dnavec Research Inc. 組織の維持および／または修復に関連する骨髄関連細胞
EP1775343A4 (de) * 2004-06-24 2007-11-14 Dnavec Research Inc Antitumormittel mit dendritischer zelle mit darin transfiziertem rna-virus
JP2008105946A (ja) * 2005-02-08 2008-05-08 Dnavec Corp 遺伝子導入造血細胞から血液細胞を再構築させる方法
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
CA2612168A1 (en) 2005-06-14 2006-12-21 Dnavec Corporation Methods for producing antibodies
WO2006137517A1 (ja) * 2005-06-24 2006-12-28 Dnavec Corporation 幼少個体への遺伝子導入用ベクター
SI1950307T1 (sl) 2005-10-28 2016-02-29 Id Pharma Co., Ltd. Transfer gena v epitelijsko matično celico dihalnih poti z uporabo lentivirusnega vektorja, psevdotipiziranega z RNA virusnim spike proteinom
JP5102630B2 (ja) * 2005-11-24 2012-12-19 ジェノミディア株式会社 改変パラミクソウイルスおよびその作製方法
CA2636600A1 (en) 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
JPWO2007139178A1 (ja) 2006-05-31 2009-10-15 ディナベック株式会社 アルツハイマー病治療薬
CA2658266A1 (en) 2006-07-13 2008-01-17 Dnavec Corporation Non-replicating paramyxoviridae virus vector
CA2677659A1 (en) 2007-02-07 2008-08-14 Dnavec Corporation Attenuated minus-stranded rna virus
US9145564B2 (en) * 2007-04-13 2015-09-29 National Institute Of Advanced Industrial Science And Technology Persistently infective Sendai virus vector
JPWO2008136438A1 (ja) 2007-04-27 2010-07-29 国立大学法人九州大学 遺伝子治療用ウイルスベクター
US9127256B2 (en) 2008-07-16 2015-09-08 Dnavec Corporation Method for production of reprogrammed cell using chromosomally unintegrated virus vector
EP2363472B1 (de) 2008-10-31 2014-12-10 Dnavec Corporation Verfahren zur verbesserung der expression rekombinanten proteins
JP5553289B2 (ja) 2009-02-27 2014-07-16 国立大学法人京都大学 新規核初期化物質
SG178197A1 (en) 2009-08-07 2012-03-29 Univ Kyoto Method of efficiently establishing induced pluripotent stem cells
US8993329B2 (en) 2009-09-24 2015-03-31 Kyoto University Method of efficiently establishing induced pluripotent stem cells
KR20120139657A (ko) * 2009-11-02 2012-12-27 고쿠리츠다이가쿠호진 미에다이가쿠 파라믹소바이러스 벡터를 사용한 비강내 분무형 결핵 백신
US8945576B2 (en) 2010-01-08 2015-02-03 Kyoto University Vaccine for treatment of tautopathy
WO2011090221A1 (en) 2010-01-22 2011-07-28 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
WO2011129446A1 (ja) 2010-04-16 2011-10-20 学校法人慶應義塾 人工多能性幹細胞の製造方法
CA2809515A1 (en) 2010-08-30 2012-03-08 Dnavec Corporation Composition for inducing pluripotent stem cell, and use thereof
US9447408B2 (en) 2010-09-14 2016-09-20 Kyoto University Method of efficiently establishing induced pluripotent stem cells
JPWO2012053646A1 (ja) 2010-10-22 2014-02-24 国立大学法人北海道大学 ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
US9506039B2 (en) 2010-12-03 2016-11-29 Kyoto University Efficient method for establishing induced pluripotent stem cells
WO2012074106A1 (ja) 2010-12-03 2012-06-07 国立大学法人京都大学 多能性幹細胞からの好酸球の製造方法
EP2674491B1 (de) * 2011-02-08 2017-06-14 Mie University Verfahren zur erzeugung eines virusvektors für einen gentransfer
JP6358706B2 (ja) * 2012-12-26 2018-07-18 バイオコモ株式会社 ヒトパラインフルエンザ２型ウイルスベクターを利用したワクチン
EP3050961B1 (de) 2013-09-24 2023-06-28 ID Pharma Co., Ltd. Verfahren zur effizienteren induzierung pluripotenter stammzellen
JPWO2016199936A1 (ja) * 2015-06-12 2018-04-05 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン
WO2018092887A1 (ja) 2016-11-17 2018-05-24 国立感染症研究所長が代表する日本国 非感染性パラミクソウイルス粒子を用いた感染症ワクチン
JP6947825B2 (ja) 2017-07-21 2021-10-13 株式会社 アイロムグループ 標的配列を改変するためのポリヌクレオチドおよびその使用
EP3744847A4 (de) 2018-01-22 2021-12-08 Japan as Represented by The Director-General of National Institute of Infectious Diseases Selektives cd8-positives t-zellinduzierendes impfstoffantigen
CN116196405A (zh) 2019-12-31 2023-06-02 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
CN116018402A (zh) 2020-09-04 2023-04-25 心脏康复株式会社 iPS细胞的品质改善剂、iPS细胞的制备方法、iPS细胞、及iPS细胞制备用组合物
KR20230126717A (ko) 2020-12-25 2023-08-30 고쿠리츠 다이가쿠 호진 교토 다이가쿠 체세포로부터의 나이브형 인간 iPS 세포 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1997016538A1 (fr) * 1995-10-31 1997-05-09 Dnavec Research Inc. Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome
WO1997016171A1 (fr) * 1995-11-01 1997-05-09 Dnavec Research Inc. Liposome a membrane fusible faisant appel a un virus sendai recombinant
CA2236378C (en) * 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
WO2000070055A1 (fr) * 1999-05-18 2000-11-23 Dnavec Research Inc. Ribonucleoproteine derivee d'un paramyxovirus

Also Published As

Publication number Publication date
ATE367445T1 (de) 2007-08-15
DK1186667T3 (da) 2007-10-22
EP1186667A4 (de) 2004-06-30
CA2368948C (en) 2013-12-24
JP2004329222A (ja) 2004-11-25
KR20070058607A (ko) 2007-06-08
ES2288473T3 (es) 2008-01-16
JP3602058B2 (ja) 2004-12-15
DE60035589T2 (de) 2008-04-17
CN1330767C (zh) 2007-08-08
AU4614600A (en) 2000-12-05
KR100739938B1 (ko) 2007-07-16
KR20020014786A (ko) 2002-02-25
CN1355851A (zh) 2002-06-26
DE60035589D1 (de) 2007-08-30
EP1186667A1 (de) 2002-03-13
WO2000070070A1 (fr) 2000-11-23
CA2368948A1 (en) 2000-11-23
EP1186667B1 (de) 2007-07-18

Similar Documents

Publication Publication Date Title
HK1044352A1 (en) Envelope gene-deficient virus vector of paramyxoviridae
JP2018531023A5 (de)
DE60033284D1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
ES2288866T3 (es) Paramixovirus que contienen una secuencia de inicio de la transcripcion modificada.
WO2003068923A3 (en) Signal for packaging of influenza virus vectors
WO2003048348A3 (en) Production of viruses, viral isolates and vaccines
IL145702A (en) Method of preparing infectious influenza viruses in the absence of a helper virus
WO2005062820A3 (en) Multi plasmid system for the production of influenza virus
YU17891A (sh) Dnk koja odgovara genomu virusa sa negativnim lancem rnk, i postupak za dobijanje infektivnih virusa sa negativnim lancem rnk
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
EP1757703A3 (de) Self-inaktivierender Gammaretrovirenvektor
CA2739963A1 (en) Lcmv-gp-vsv pseudotyped vectors and tumor infiltrating virus-producing cells for the therapy of tumors
JP2006509523A5 (de)
AU7282787A (en) A cell line producing aids viral antigens without producing infectious virus particles
DE69128898D1 (de) Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
WO2004055161A3 (en) Large scale production of packaged alphavirus replicons
ATE103328T1 (de) Fuer ein glykoprotein des aids-virus kodierende virus-vektoren, vakzin und antikoerper.
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
WO2003092582A3 (en) Chimeric ebola virus envelopes and uses therefor
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
BR0015740A (pt) Mutações de faixa de hospedeiro de vìrus de membrana e seus usos como substratos de vacinas
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
CA2099268A1 (en) Fusions of a viral protein and a destructive enzyme
WO2003029274A3 (en) Paramyxoviruses as gene transfer vectors to lung cells
WO1999020742A3 (en) A packaging cell line producing siv-pseudotyped mlv

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120518